New horizons in the analysis of circulating cell-derived microparticles

Keio Journal of Medicine

Volumn 53, Issue 4, 2004, Pages 210-230

  Horstman, Lawrence L ^a   Jy, Wenche ^a   Jimenez, Joaquin J ^a   Bidot, Carlos ^a   Ahn, Yeon S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cell derived microparticles; Inflammation; Platelet microparticles

Indexed keywords

ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10A; CD31 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CHEMOKINE RECEPTOR; CHYLOMICRON; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; FRACTALKINE; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN; INTERSTITIAL COLLAGENASE; LIPOCORTIN 5; LIPOSOME; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PROCOAGULANT; PROTEIN C; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL DERIVED MICROPARTICLE; CLINICAL LABORATORY; COMPLEMENT SYSTEM; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNITY; INFLAMMATION; MEASUREMENT; MEMBRANE VESICLE; METASTASIS; NUCLEOSOME; PARTICLE SIZE; PLATELET MICROPARTICLE; REVIEW; THROMBOCYTE; THROMBOSIS;

BIOLOGICAL MARKERS; BLOOD PLATELETS; ENDOTHELIAL CELLS; HUMANS; PARTICLE SIZE; THROMBOSIS;

EID: 12344303983     PISSN: 00229717     EISSN: None     Source Type: Journal    
DOI: 10.2302/kjm.53.210     Document Type: Review

References (295)

1. Horstman LL, Ahn YS: Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999; 30: 111-142
2. Horstman LL, Jy W, Jimenez JJ, Ahn YS: Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9: 1118-1135
3. Nomura S: Function and clinical significance of platelet-derived microparticles. Int J Hematol 2001; 74: 397-404
4. Freyssinet JM: Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1: 1655-1662
5. Miyazaki Y, Nomura S, Miyake T, Kagawa H, Kitada C, Taniguchi H, Komiyama Y, Fujimura Y, Ikeda Y, Fukuhara S: High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996; 88: 3456-3464
6. Baumgart T, Hess ST, Webb WW: Imaging coexisting fluid domains in biomembrane models coupling curvature and line tension. Nature 2003; 425: 821-824
7. George JN, Thoi LL, McManus LM, Reimann TA: Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982; 60: 834-840
8. Kokawa T, Nomura S, Yanabu M, Yasunaga K: Detection of platelet antigen for antiplatelet antibodies in idiopathic thrombocytopenic purpura by flow cytometry, antigen-capture ELISA, and immunoblotting: a comparative study. Eur J Haematol 1993; 50: 74-80
9. Osumi K, Ozeki Y, Saito S, Nagamura Y, Ito H, Kimura Y, Ogura H, Nomura S: Development and assessment of enzyme immunoassay for platelet-derived microparticles. Thromb Haemost 2001; 85: 326-330
10. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T: Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004; 91: 146-154
11. Miyamoto S, Marcinkiewicz C, Edmunds LH Jr, Niewiarowski S: Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GPIIb/IIIa. Thromb Haemost 1998; 80: 225-230
12. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A: Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 1999; 99: 348-353
13. Fourcade O, Simon MF, Viode C, Rugani N, Leballe F, Ragab A, Fournie B, Sarda L, Chap H: Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells. Cell 1995; 80: 919-927
14. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A: Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843
15. Aupeix K, Hugel B, Martin T, Bischoff P, Lill H, Pasquali JL, Freyssinet JM: The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection. J Clin Invest 1997; 99: 1546-1554
16. Joop K, Berckmans RJ, Nieuwland R, Berkhout J, Romijn FP, Hack CE, Sturk A: Microparticles from patients with multiple organ dysfunction syndrome and sepsis support coagulation through multiple mechanisms. Thromb Haemost 2001; 85: 810-820
17. VanWijk MJ, Boer K, Berckmans RJ, Meijers JC, van der Post JA, Sturk A, VanBavel E, Nieuwland R: Enhanced coagulation activation in preeclampsia: the role of APC resistance, microparticles and other plasma constituents. Thromb Haemost 2002; 88: 415-420
18. VanWijk MJ, Nieuwland R, Boer K, van der Post JA, VanBavel E, Sturk A: Microparticle subpopulations are increased in preeclampsia: possible involvement in vascular dysfunction? Am J Obstet Gynecol 2002; 187: 450-456
19. Vanwijk MJ, Svedas E, Boer K, Nieuwland R, Vanbavel E, Kublickiene KR: Isolated microparticles, but not whole plasma, from women with preeclampsia impair endothelium-dependent relaxation in isolated myometrial arteries from healthy pregnant women. Am J Obstet Gynecol 2002; 187: 1686-1693
20. Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut JG, Arnoux D, Charpiot P, Freyssinet JM, Oliver C, et al: Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002; 51: 2840-2845
21. Bretelle F, Sabatier F, Desprez D, Camoin L, Grunebaum L, Combes V, D'Ercole C, Dignat-George F: Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost 2003; 89: 486-492
22. Frenkel EJ, Kuypers FA, Op den Kamp JA, Roelofsen B, Ott P: Effect of membrane cholesterol on dimyristoylphosphatidylcholine-induced vesiculation of human red blood cells. Biochim Biophys Acta 1986; 855: 293-301
23. Gonzalez-Quintero VH, Jimenez JJ, Jy W, Mauro LM, Hortman L, O'Sullivan MJ, Ahn Y: Elevated plasma endothelial microparticles in preeclampsia. Am J Obstet Gynecol 2003; 189: 589-593
24. Charo IF, Kieffer N, Phillips DR: Platelet membrane glycoproteins. In: Robert W. Colman et al. eds, Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th Ed, PA, Philadelphia, Lippincott Williams & Wilkins, 2001; Ch. 22
25. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, Zelmanovic D, Newland A: Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem 2002; 48: 891-899
26. Philippe J, De Logi E, Baele G: Comparison of five different citrated tubes and their in vitro effects on platelet activation. Clin Chem 2004; 50: 656-658
27. Ahnadi CE, Sabrinah Chapman E, Lepine M, Okrongly D, Pujol-Moix N, Hernandez A, Boughrassa F, Grant AM: Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy. Thromb Haemost 2003; 90: 940-948
28. Hoffmeister KM, Josefsson EC, Isaac NA, Clausen H, Hartwig JH, Stossel TP: Glycosylation restores survival of chilled blood platelets. Science 2003; 301: 1531-1534
29. Tablin F, Gousset K, Field CL, Crowe JH: Cold-induced platelet raft aggregation requires actin cytoskeletal reorganization, and is calcium independent. Blood 2002; 100(11): 63b #3723
30. Gousset K, Tsvetkova NM, Crowe JH, Tablin F: Important role of raft aggregation in the signaling events of cold-induced platelet activation. Biochim Biophys Acta 2004; 1660: 7-15
31. Bowron A, Stansbie D: Addition of 3-deazaadenosine to vacutainer tubes stabilizes whole-blood homocysteine for at least 6 hours at ambient temperature. Clin Chem 2003; 49: 835
32. Clark S, Youngman LD, Sullivan J, Peto R, Collins R: Stabilization of homocysteine in unseparated blood over several days: a solution for epidemiological studies. Clin Chem 2003; 49: 518-520
33. Parodi O, Baudo F, Devoto E, Campolo J, Parodi G, Parolini M, Caruso R, Brunelli C, Accinni R: Blood glutathione detects prooxidant patterns in patients with mild hyperhomocysteinemia at risk for atherosclerotic vascular events. Blood 2002; 100(11): 112b #3926
34. Walsh GM, Sheehan D, Kinsella A, Moran N, O'Neill S: Redox modulation of integrin [correction of integin] alpha IIb beta 3 involves a novel allosteric regulation of its thiol isomerase activity. Biochemistry 2004; 43: 473-480
35. Pasquet JM, Toti F, Nurden AT, Dachary-Prigent J: Procoagulant activity and active calpain in platelet-derived microparticles. Thromb Res 1996; 82: 509-522
36. Wiedmer T, Shattil SJ, Cunningham M, Sims PJ: Role of calcium and calpain in complement-induced vesiculation of the platelet plasma membrane and in the exposure of the platelet factor Va receptor. Biochemistry 1990; 29: 623-632
37. Jackson SP, Kanagasundaram V, Kulkarni S: Phenotypic conversion of platelets from a prothrombotic to a proinflammatory adhesive state: involvement of the calcium-dependent thiol protease, calpain. Blood 2003; 102(11): 66b #3968
38. Lindenblatt N, Schareck W, Belusa L, Maria Nickels R, Dieter Menger M, Vollmar B: Anti-oxidant ebselen delays microvascular thrombus formation in the rat cremaster muscle by inhibiting platelet P-selectin expression. Thromb Haemost 2003; 90: 882-892
39. Xia L, Pan J, Yao L, McEver RP: A proteasome inhibitor, an antioxidant, or a salicylate, but not a glucocorticoid, blocks constitutive and cytokine-inducible expression of P-selectin in human endothelial cells. Blood 1998; 91: 1625-1632
40. Del Principe D, Frega G, Palumbo G: Platelet-leukocyte interactions: platelets possess an antioxidant armamentarium. Thromb Haemost 2003; 90: 759-760
41. Bode AP, Knupp CL: Platelet vesiculation and loss of GP Ib during storage at 4°C. Thromb Haemost 1991; 65(6): 1072 #356
42. Jy W, Horstman LL, Arce M, Ahn YS: Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119: 334-345
43. von Ahsen N, Ehrlich B, Scott CS, Riggert J, Oellerich M: Cryoglobulins interfere with platelet counts by optical and impedance methods but not with the CD61 immunoplatelet count. Clin Chem 2001; 47: 1858-1860
44. Leo L, Di Paola J, Judd BA, Koretzky GA, Lentz SR: Role of the adapter protein SLP-76 in GPVI-dependent platelet procoagulant responses to collagen. Blood 2002; 100: 2839-2844
45. Nomura S, Yanabu M, Kido H, Lan XG, Ichiyoshi H, Katsura K, Miyake T, Miyazaki Y, Kagawa H, Fukuhara S: Significance of cytokines and CD68-positive microparticles in immune thrombocytopenic purpura. Eur J Haematol 1995; 55: 49-56
46. Harris EN, Pierangeli S, Birch D: Anticardiolipin wet workshop report. Fifth International Symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 101: 616-624
47. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GR, et al: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42: 1309-1311
48. Morel O, Jesel L, Chauvin M, Freyssinet JM, Toti F: Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. J Thromb Haemost 2003; 1: 2685-2687
49. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ: Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990; 75: 128-138
50. Shattil SJ, Cunningham M, Hoxie JA: Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315
51. Michelson AD: Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 4925-4936
52. Jy W, Mao WW, Horstman LL, Valant PA, Ahn YS: A flow cytometric assay of platelet activation marker P-selectin (CD62P) distinguishes heparin-induced thrombocytopenia (HIT) from HIT with thrombosis (HITT). Thromb Haemost 1999; 82: 1255-1259
53. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K: Reversibility versus persistence of GPIIb/ IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther 2004; 308: 1002-1011
54. Forastiero R, Martinuzzo M, Carreras LO, Maclouf J: Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. Thromb Haemost 1998; 79: 42-45
55. Barry MC, Kelly CJ, Stokes K, Abdih H, Sheehan S, Burke P, Bouchier Hayes D: Glyceryl trinitrate prevents neutrophil activation but not thromboxane release following ischaemia-reperfusion injury. Br J Surg 1996; 83: 1095-1100
56. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S: Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 1993; 70: 667-671
57. Van Lente F: Markers of inflammation as predictors in cardiovascular disease. Clin Chim Acta 2000; 293: 31-52
58. Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, Goodall AH, Michelson AD, Nurden AT, Shankey TV: European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost 1998; 79: 885-896
59. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS: Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109: 175-180
60. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Soderland C, Ahn YS: Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willebrand factor and markers of endothelial activation. Br J Haematol 2003; 123: 896-902
61. Losy J, Niezgoda A, Wender M: Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions. J Neuroimmunol 1999; 99: 169-172
62. Jimenez JJ, Jy W, Mauro LM, Horstman LL, Ahn YS: Elevated endothelial microparticles in thrombotic thrombocytopenic purpura: findings from brain and renal microvascular cell culture and patients with active disease. Br J Haematol 2001; 112: 81-90
63. Minagar A, Jy W, Jimenez JJ, Sheremata WA, Mauro LM, Mao WW, Horstman LL, Ahn YS: Elevated plasma endothelial microparticles in multiple sclerosis. Neurology 2001; 56: 1319-1324
64. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, de Marchena E, Ahn YS: High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145: 962-970
65. Roldan V, Marin F, Lip GY, Blann AD: Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 2003; 90: 1007-1020
66. Semaan HB, Gurbel PA, Anderson JL, Muhlestein JB, Carlquist JF, Horne BD, Serebruany VL: Soluble VCAM-1 and E-selectin, but not ICAM-1 discriminate endothelial injury in patients with documented coronary artery disease. Cardiology 2000; 93: 7-10
67. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E: Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96: 4219-4225
68. Lieuw-a-Fa M, Schalkwijk C, van Hinsbergh VW: Distinct accumulation patterns of soluble forms of E-selectin, VCAM-1 and ICAM-1 upon infusion of TNFalpha in tumor patients. Thromb Haemost 2003; 89: 1052-1057
69. Jy W, Jimenez JJ, Mauro LM, Horstman LL, Bidot CJ, Tiede MP, Ahn E, Ahn YS: Endothelial microparticles (EMP) interact with platelets via a vWF dependent pathway to form platelet aggregates, more resistent to dissociation than those induced by soluble vWF. Blood 2003; 102(11): 783a #2896
70. Satta N, Freyssinet JM, Toti F: The significance of human monocyte thrombomodulin during membrane vesiculation and after stimulation by lipopolysaccharide. Br J Haematol 1997; 96: 534-542
71. Amirkhosravi A, Meyer T, Sackel D, Desai H, Biddinger R, Amaya M, Francis JL: Platelet microparticles upregulate TF and VEGF in endothelial and melanoma cells in a CD40 ligand-dependent manner: Possible role in angiogenesis and metastasis. Blood 2002; 100(11): 63b #3721
72. Heaney ML, Golde DW: Soluble cytokine receptors. Blood 1996; 87: 847-857
73. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT: Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost 2004; 91: 4-15
74. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y: Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96: 170-175
75. Camire RM, Pollak ES, Kaushansky K, Tracy PB: Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998; 92: 3035-3041
76. Colman RW: Where does platelet factor V originate? Blood 1999; 93: 3152-3153
77. Sun H, Yang TL, Yang A, Wang X, Ginsburg D: The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis. Blood 2003; 102: 2856-2861
78. Yang TL, Pipe SW, Yang A, Ginsburg D: Biosynthetic origin and functional significance of murine platelet factor V. Blood 2003; 102: 2851-2855
79. Bode AP, Sandberg H, Dombrose FA, Lentz BR: Association of factor V activity with membranous vesicles released from human platelets: requirement for platelet stimulation. Thromb Res 1985; 39: 49-61
80. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ: Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988; 263: 18205-18212
81. Veljkovic DK, Cramer EM, Alimardani G, Fichelson S, Masse JM, Hayward CP: Studies of alpha-granule proteins in cultured human megakaryocytes. Thromb Haemost 2003; 90: 844-852
82. Fink L, Holschermann H, Kwapiszewska G, Muyal JP, Lengemann B, Bohle RM, Santoso S: Characterization of platelet-specific mRNA by real-time PCR after laser-assisted microdissection. Thromb Haemost 2003; 90: 749-756
83. Garcia A, Prabhakar S, Hughan S, Anderson TW, Brock CJ, Pearce AC, Dwek RA, Watson SP, Hebestreit HF, Zitzmann N: Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood 2004; 103: 2088-2095
84. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB: Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-2104
85. Jy W, Horstman LL, Wang F, Duncan RC, Ahn YS: Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Thromb Res 1995; 80: 471-482
86. Rand MD, Kalafatis M, Mann KG: Platelet coagulation factor Va: the major secretory platelet phosphoprotein. Blood 1994; 83: 2180-2190
87. Zillmann A, Luther T, Muller I, Kotzsch M, Spannagl M, Kauke T, Oelschlagel U, Zahler S, Engelmann B: Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 2001; 281: 603-609
88. Goodall AH, Jones CI, Lamb DJ, Tull SP, Payne DA, Appleby JA: Blood borne tissue factor is present on platelets in the absence of leukocyte microparticles. Blood 2002; 100(11): 56a #200
89. Siddiqui FA, Desai H, Amirkhosravi A, Siddiqui TF, Meyer T, Amaya M, Francis JL: Platelet microparticles from healthy donors contain tissue factor. Blood 2002; 100(11): 497a #1936
90. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, Engelmann B: Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J 2003; 17: 476-478
91. Scholz T, Temmler U, Krause S, Heptinstall S, Losche W: Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost 2002; 88: 1033-1038
92. Amirkhosravi A, Alexander M, May K, Francis DA, Warnes G, Biggerstaff J, Francis JL: The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87-95
93. Osterud B: The role of platelets in decrypting monocyte tissue factor. Semin Hematol 2001; 38: 2-5
94. Nomura S, Komiyama Y, Matsuura E, Kokawa T, Takahashi H, Koike T: Binding of beta 2-glycoprotein I to platelet-derived microparticles. Br J Haematol 1993; 85: 639-640
95. Nomura S, Yanabu M, Miyake T, Miyazaki Y, Kido H, Kagawa H, Fukuhara S, Komiyama Y, Matsuura E, Koike T: Relationship of microparticles with beta 2-glycoprotein I and P-selectin positivity to anticardiolipin antibodies in immune thrombocytopenic purpura. Ann Hematol 1995; 70: 25-30
96. Roubey RA, Pratt CW, Buyon JP, Winfield JB: Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90: 1100-1104
97. Navarro M, Cervera R, Teixido M, Reverter JC, Font J, Lopez-Soto A, Monteagudo J, Escolar G, Ingelmo M: Antibodies to endothelial cells and to beta 2-glycoprotein I in the antiphospholipid syndrome: prevalence and isotype distribution. Br J Rheumatol 1996; 35: 523-528
98. Vallar L, Regnault V, Latger-Cannard V, Lecompte T: Beta2-glycoprotein I binding to platelet microparticle membrane specifically reduces immunoreactivity of glycoproteins IIb/IIIa. Thromb Haemost 2001; 85: 314-319
99. Salemink I, Blezer R, Willems GM, Galli M, Bevers E, Lindhout T: Antibodies to beta2-glycoprotein I associated with antiphospholipid syndrome suppress the inhibitory activity of tissue factor pathway inhibitor. Thromb Haemost 2000; 84: 653-656
100. Merrill JT, Zhang HW, Shen C, Butman BT, Jeffries EP, Lahita RG, Myones BL: Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost 1999; 81: 748-757
101. Mori T, Takeya H, Nishioka J, Gabazza EC, Suzuki K: beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface. Thromb Haemost 1996; 75: 49-55
102. Tans G, Rosing J, Thomassen MC, Heeb MJ, Zwaal RF, Griffin JH: Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles. Blood 1991; 77: 2641-2648
103. Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A: Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646
104. Schmaier AH: The physiologic basis of assembly and activation of the plasma kallikrein/kinin system. Thromb Haemost 2004; 91: 1-3
105. Weiler H, Isermann BH: Thrombomodulin. J Thromb Haemost 2003; 1: 1515-1524
106. Marlar RA: The protein C system - how complex is it? Thromb Haemost 2001; 85: 756-757
107. Esmon CT: The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-145
108. Esmon CT: Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29: S48-51
109. Dahlback B, Villoutreix BO: Molecular recognition in the protein C anticoagulant pathway. J Thromb Haemost 2003; 1: 1525-1534
110. Leurs J, Nerme V, Sim Y, Hendriks D: Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-423
111. Gris JC, Toulon P, Brun S, Maugard C, Sarlat C, Schved JF, Berlan J: The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Thromb Haemost 1996; 76: 38-45
112. Rezende SM, Simmonds RE, Lane DA: Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 2004; 103: 1192-1201
113. Esmon CT: The endothelial cell protein C receptor. Thromb Haemost 2000; 83: 639-643
114. Stearns-Kurosawa DJ, Swindle K, D'Angelo A, Della Valle P, Fattorini A, Caron N, Grimaux M, Woodhams B, Kurosawa S: Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood 2002; 99: 526-530
115. Saposnik B, Reny JL, Gaussem P, Emmerich J, Aiach M, Gandrille S: A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosis. Blood 2004; 103: 1311-1318
116. Samis JA, Garrett M, Manuel RP, Nesheim ME, Giles AR: Human neutrophil elastase activates human factor V but inactivates thrombin-activated human factor V. Blood 1997; 90: 1065-1074
117. Takahashi H, Hanano M, Wada K, Tatewaki W, Niwano H, Tsubouchi J, Nakano M, Nakamura T, Shibata A: Circulating thrombomodulin in thrombotic thrombocytopenic purpura. Am J Hematol 1991; 38: 174-177
118. Varadi K, Siekmann J, Turecek PL, Schwarz HP, Marder VJ: Phospholipid-bound tissue factor modulates both thrombin generation and APC-mediated factor Va inactivation. Thromb Haemost 1999; 82: 1673-1679
119. Dudek AZ, Pennell CA, Key NS, Slungaard A: Platelet factor 4 (PF4) binds to both the GAG domain of thrombomodulin and the GLA domain of protein C: potential role in the regulation of clotting (abstract). J Invest Med 1996; 44(3): 213A
120. Rezaie AR: Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-15570
121. Joyce DE, Grinnell BW: Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med 2002; 30: S288-293
122. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150
123. Taylor FB Jr, Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, Kosanke S, Peer G, Esmon CT: The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680-1686
124. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G 3rd, et al; PROWESS Sepsis Study Group: Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003; 90: 642-653
125. Ogura H, Kawasaki T, Tanaka H, Koh T, Tanaka R, Ozeki Y, Hosotsubo H, Kuwagata Y, Shimazu T, Sugimoto H: Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-809
126. Ogura H, Kawasaki T, Tanaka H, Koh T, Tanaka R, Ozeki Y, Hosotsubo H, Kuwagata Y, Shimazu T, Sugimoto H: Activated platelets enhance microparticle formation and platelet-leukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50: 801-809
127. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG, Hack CE, Sturk A: Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000; 95: 930-935
128. Soriano AO, Jy W, Valdivia MA, Velasquez HS, Chirinos J, Tiede MP, Ahn E, Kett D, Horstman LL, Jimenez JJ, Ahn YS: Reduced endothelial and platelet microparticles and their interaction with leukocytes correlate with organ dysfunction and predict mortality in severe sepsis. Blood 2003; 102: 58b #3934
129. Fox JE, Austin CD, Boyles JK, Steffen PK: Role of the membrane skeleton in preventing the shedding of procoagulant-rich microvesicles from the platelet plasma membrane. J Cell Biol 1990; 111: 483-493
130. Behnke O, Forer A: Blood platelet heterogeneity: evidence for two classes of platelets in man and rat. Br J Haematol 1993; 84: 686-693
131. Kunicki TJ, Orchekowski R, Annis D, Honda Y: Variability of integrin alpha 2 beta 1 activity on human platelets. Blood 1993; 82: 2693-2703
132. Johnston GI, Pickett EB, McEver RP, George JN: Heterogeneity of platelet secretion in response to thrombin demonstrated by fluorescence flow cytometry. Blood 1987; 69: 1401-1403
133. Frojmovic M, Wong T: Dynamic measurements of the platelet membrane glycoprotein IIb-IIIa receptor for fibrinogen by flow cytometry. II. Platelet size-dependent subpopulations. Biophys J 1991; 59: 828-837
134. Jung SM, Tanoue K, Yamazaki H: The electrophoretic mobility heterogeneity of human platelet subpopulations of different buoyant densities. Thromb Haemost 1985; 53: 188-194
135. Dhar A, Ganguly P: Lectin fractionation of rabbit blood platelets: isolation of subpopulations of different ages. Prog Clin Biol Res 1988; 283: 77-81
136. Kienast J, Schmitz G: Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990; 75: 116-121
137. Michelson AD: Flow cytometric detection of distinct subpopulations of platelets in individual patients. Prog Clin Biol Res 1988; 283: 131-136
138. Holmes CE, Bouchard BA, Barbick RR, Safdar H, Tracy PB: The existence of platelet subpopulations in patients with myeloproliferative disease: preliminary correlation with clinically abnormal hemostasis. Blood 2003; 102(11): 787a #2909
139. Jy W, Horstman LL, Homolak D, Ahn YS: Electrophoretic properties of platelets from normal, thrombotic and ITP patients by doppler electrophoretic light scattering analysis. Platelets 1995; 6: 354-58
140. Herd CM, Page CP: Do platelets have a role as inflammatory cells? In: Joseph M, ed, Immunopharmacology of Platelets, London/New York, Academic Press, 1995: 1-12
141. Weyrich AS, Lindemann S, Zimmerman GA: The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897-1905
142. Iwamoto S, Kawasaki T, Kambayashi J, Ariyoshi H, Monden M: Platelet microparticles: a carrier of platelet-activating factor? Biochem Biophys Res Commun 1996; 218: 940-944
143. Murakami K, Okajima K, Uchiba M, Johno M, Okabe H, Takatsuki K: A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. Thromb Haemost 1996; 75: 965-970
144. Siebeck M, Weipert J, Keser C, Kohl J, Spannagl M, Machleidt W, Schweiberer L: A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine. J Trauma 1991; 31: 942-949
145. Qayumi AK, Jamieson WR, Poostizadeh A: Effects of platelet-activating factor antagonist CV-3988 in preservation of heart and lung for transplantation. Ann Thorac Surg 1991; 52: 1026-1032
146. Meade CJ, Heuer H, Kempe R: Biochemical pharmacology of platelet-activating factor (and PAF antagonists) in relation to clinical and experimental thrombocytopenia. Biochem Pharmacol 1991; 41: 657-668
147. James-Kracke MR, Sexe RB, Shukla SD: Picomolar platelet-activating factor mobilizes Ca to change platelet shape without activating phospholipase C or protein kinase C; simultaneous fluorometric measurement of intracellular free Ca concentration and aggregation. J Pharmacol Exp Ther 1994; 271: 824-831
148. Lindsberg PJ, Hallenbeck JM, Feuerstein G: Platelet-activating factor in stroke and brain injury. Ann Neurol 1991; 30: 117-129
149. Pitsilos S, Hunt J, Mohler ER, Prabhakar AM, Poncz M, Dawicki J, Khalapyan TZ, Wolfe ML, Fairman R, Mitchell M, Carpenter J, Golden MA, Cines DB, Sachais BS: Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost 2003; 90: 1112-1120
150. Aziz KA, Cawley JC, Zuzel M: Platelets prime PMN via released PF4: mechanism of priming and synergy with GM-CSF. Br J Haematol 1995; 91: 846-853
151. Pabst MJ: Priming of neutrophils, In: Hellwell PG, ed, Immunopharmacology of neutrophils, Williams TJ, London/New York, Academic Press, 1994: 195-221
152. Visentin GP, Ford SE, Scott JP, Aster RH: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-88
153. Capitanio AM, Niewiarowski S, Rucinski B, Tuszynski GP, Cierniewski CS, Hershock D, Kornecki E: Interaction of platelet factor 4 with human platelets. Biochim Biophys Acta 1985; 839: 161-173
154. McGregor JL: The role of human platelet membrane receptors in inflamation [Ch 4]. In: Joseph M, ed. Immunopharmacology of Platelets. London/New York: Academic Press, 1995: 66-82
155. Berger G, Masse JM, Cramer EM: Alpha-granule membrane mirrors the platelet plasma membrane and contains the glycoproteins Ib, IX, and V. Blood 1996; 87: 1385-1395
156. Israels SJ, McMillan-Ward EM, Easton J, Robertson C, McNicol A: CD63 associates with the alphaIIb beta3 integrin-CD9 complex on the surface of activated platelets. Thromb Haemost 2001; 85: 134-141
157. White JG: Platelet membrane ultrastructure and its changes during platelet activation. In: Jamieson GA, ed. Platelet Membrane Receptors: Molecular Biology, Immunology, Biochemistry and Pathology. NY: Alan R. Liss Inc, 1988: 1-32
158. Pimanda JE, Annis DS, Raftery M, Mosher DF, Chesterman CN, Hogg PJ: The von Willebrand factor-reducing activity of thrombospondin-1 is located in the calcium-binding/C-terminal sequence and requires a free thiol at position 974. Blood 2002; 100: 2832-2838
159. Carron JA, Bates RC, Smith AI, Tetoz T, Arellano A, Gordon DL, Burns GF: Factor H co-purifies with thrombospondin isolated from platelet secretate. Biochim Biophys Acta 1996; 1289: 305-311
160. Hawrylowicz CM, Santoro SA, Platt FM, Unanue ER: Activated platelets express IL-1 activity. J Immunol 1989; 143: 4015-4018
161. Hawrylowicz CM, Howells GL, Feldmann M: Platelet-derived interleukin 1 induces human endothelial adhesion molecule expression and cytokine production. J Exp Med 1991; 174: 785-790
162. MacKenzie A, Wilson HL, Kiss-Toth E, Dower SK, North RA, Surprenant A: Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 2001; 15: 825-835
163. Loppnow H, Bil R, Hirt S, Schonbeck U, Herzberg M, Werdan K, Rietschel ET, Brandt E, Flad HD: Platelet-derived interleukin-1 induces cytokine production, but not proliferation of human vascular smooth muscle cells. Blood 1998; 91: 134-141
164. Kameyoshi Y, Schroder JM, Christophers E, Yamamoto S: Identification of the cytokine RANTES released from platelets as an eosinophil chemotactic factor. Int Arch Allergy Immunol 1994; 104: 49-51
165. Klinger MH, Wilhelm D, Bubel S, Sticherling M, Schroder JM, Kuhnel W: Immunocytochemical localization of the chemokines RANTES and MIP-1 alpha within human platelets and their release during storage. Int Arch Allergy Immunol 1995; 107: 541-546
166. Bubel S, Wilhelm D, Entelmann M, Kirchner H, Kluter H: Chemokines in stored platelet concentrates. Transfusion 1996; 36: 445-449
167. Horstman LL, Valle-Riestra BJ, Jy W, Wang F, Mao W, Ahn YS: Desmopressin (DDAVP) acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb Res 1995; 79: 163-174
168. Ghosh S, Rao AK: Lack of effect of 1-desamino-8-D-arginine vasopressin on direct adhesion of platelets to collagen. Thromb Res 1993; 70: 417-422
169. Yang X, Disa J, Rao AK: Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. Thromb Res 1990; 59: 809-818
170. Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B: Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. Blood 2003; 102: 4594-4599
171. Jy W, Haynes DH: Intracellular calcium storage and release in the human platelet. Chlorotetracycline as a continuous monitor. Circ Res 1984; 55: 595-608
172. Billy D, Speijer H, Zwaal RF, Hack EC, Hermens WT: Anticoagulant and membrane-degrading effects of secretory (nonpancreatic) phospholipase A2 are inhibited in plasma. Thromb Haemost 2002; 87: 978-984
173. Anand SX, Viles-Gonzalez JF, Badimon JJ, Cavusoglu E, Marmur JD: Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003; 90: 377-384
174. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA: The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 98: 1047-1054
175. Hermann A, Rauch BH, Braun M, Schror K, Weber AA: Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82
176. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ: CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 2003; 92: 1041-1048
177. Krueger LA, Furman MI, Barnard MR, Frelinger AL, Michelson AD: Release of soluble CD40L from platelets is regulated by fibrinogen binding to GPIIb-IIIa, actin polymerizatin, and a matrix matalloproteinase. Blood 2002; 100(11): 251a #952
178. Schafer A, Schulz C, Eigenthaler M, Fraccarollo D, Kobsar A, Gawaz M, Ertl G, Walter U, Bauersachs J: Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion. Blood 2004; 103: 407-412
179. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN: Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000; 96: 4046-4054
180. Wang JF, Liu ZY, Groopman JE: The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 1998; 92: 756-764
181. Rozmyslowicz T, Murphy SL, Conover DO, Wroblewski K, Ratajczak MZ, Gaulton GN: The role of microparticles in HIV-1 infection. Blood 2003; 102(11): 278a #987
182. Sheng GY, Huang XL, Bai ST: Study on CXCR4 receptor on megakaryocytes and its ligand in bone marrow in children with acute idiopathic thrombocytopenic purpura. Blood 2003; 102(11): 65b #3962
183. Mack M, Kleinschmidt A, Bruhl H, Klier C, Nelson PJ, Cihak J, Plachy J, Stangassinger M, Erfle V, Schlondorff D: Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. Nat Med 2000; 6: 769-775
184. Momoi A, Tsukada N, Nishio M, Aoki S, Fuse I, et al: Platelets express functional BAFF, which can support B cell survival. Blood 2003; 102(11): 57b #3930
185. Janowska-Wieczorek A, Kijowski J, Marquez LA, Ratajczak J, Ratajczak MZ: Microvesicles derived from activated platelets: an under-appreciated modulator of the metastatic potential of tumor cells. Blood 2003; 102(11): 73b #3998
186. Jurasz P, Alonso D, Castro-Blanco S, Murad F, Radomski MW: Generation and role of angiostatin in human platelets. Blood 2003; 102: 3217-3223
187. Ma L, Hollenberg MD, Wallace JL: Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol 2001; 134: 701-704
188. Carrell R: And a final message from antithrombin (Editorial). Blood 2004; 103: 1179
189. Bahou WF: Thrombin's faces revealed: cellular effects include induction of neoangiogenesis. J Thromb Haemost 2003; 1: 2078-2080
190. Belting M, Dorrell M, Sandgren S, Ahamad J, Dorfleutner A, Carmeliet P, Mueller B, Friedlander M, Ruf W: Tissue factor signalling in angiogenesis. Blood 2003; 102(11): 13a #33
191. Taraboletti G, Roberts D, Liotta LA, Giavazzi R: Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990; 111: 765-772
192. Folkman J, Kalluri R: Cancer without disease. Nature 2004; 427: 787
193. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS: Extracellular membrane vesicles from tumor cells promote angiogenesis via sphingomyelin. Cancer Res 2002; 62: 6312-6317
194. Kim HK, Song KS, Park YS, Kang YH, Lee YJ, Lee KR, Kim HK, Ryu KW, Bae JM, Kim S: Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003; 39: 184-191
195. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, Holmgren L: Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 2001; 98: 6407-6411
196. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, et al: Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7: 297-303
197. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996; 183: 1161-1172
198. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600
199. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, Watts C: An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 1998; 396: 695-699
200. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ: Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791-3799
201. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ: Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113: 3365-3374
202. Fritzsching B, Schwer B, Kartenbeck J, Pedal A, Horejsi V, Ott M: Release and intercellular transfer of cell surface CD81 via microparticles. J Immunol 2002; 169: 5531-5537
203. Abrams C, Shattil SJ: Immunological detection of activated platelets in clinical disorders. Thromb Haemost 1991; 65: 467-473
204. Kannan K, Divers SG, Lurie AA, Chervenak R, Fukuda M, Holcombe RF: Cell surface expression of lysosome-associated membrane protein-2 (lamp2) and CD63 as markers of in vivo platelet activation in malignancy. Eur J Haematol 1995; 55: 145-151
205. Ciferri S, Emiliani C, Guglielmini G, Orlacchio A, Nenci GG, Gresele P: Platelets release their lysosomal content in vivo in humans upon activation. Thromb Haemost 2000; 83: 157-164
206. Borregaard N, Kjeldsen L, Lollike K, Sengelov H: Granules and vesicles of human neutrophils. The role of endomembranes as source of plasma membrane proteins. Eur J Haematol 1993; 51: 318-322
207. Majka M, Zupanska B, Ratajczak MZ: Evidence that platelet-derived microvesicles transfer HPA1a antigen to the surface of both endothelial cells and CD34+ hematopoietic stem/progenitor cells: a new perspective on the pathogenesis of immune thrombocytopenia. Blood 2003; 102(11): 294a #1051
208. Hilf N, Singh-Jasuja H, Schwarzmaier P, Gouttefangeas C, Rammensee HG, Schild H: Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood 2002; 99: 3676-3682
209. Patel DM, Arnold PY, White GA, Nardella JP, Mannie MD: Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol 1999; 163: 5201-5210
210. Kolodny L, Ahn YS, Jy W, Horstman LL, Sheremata WA: Evidence of platelet activation in multiple sclerosis. Ann Neurol 1996; 40: 520 #M117
211. Jimenez JJ, Jy W, Mauro LM, Minagar A, Solderland C, Horstman LL, Ahn YS: Transendothelial migration (TEM) in multiple sclerosis (MS): induction by patient plasma and its augmentation by leukocyte-endothelial microparticle (L-EMP) complexes. Blood 2003; 102(11): 72b #3994
212. Jy W, Jimenez JJ, Minagar A, Mauro L, Horstman LL, Bidot CJ, Sheremata WA, Ahn YS: Endothelial microparticles (EMP) enhance adhesion and transmigration of monocytes: EMP-monocyte conjugates as a marker of disease activity in multiple sclerosis (MS). Blood 2002; 100(11): 460a #1783
213. McEver RP: Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86: 746-756
214. Elzey BD, Tian J, Jensen RJ, Swanson AK, Lees JR, Lentz SR, Stein CS, Nieswandt B, Wang Y, Davidson BL, et al: Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9-19
215. Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM: Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 1992; 176: 587-592
216. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimaki A, Heikinheimo M, Joensuu H, et al: Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998; 80: 171-175
217. Albanese J, Meterissian S, Kontogiannea M, Dubreuil C, Hand A, Sorba S, Dainiak N: Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood 1998; 91: 3862-3874
218. Banga HS, Walker RK, Winberry LK, Rittenhouse SE: Pertussis toxin can activate human platelets. Comparative effects of holotoxin and its ADP-ribosylating S1 subunit. J Biol Chem 1987; 262: 14871-14874
219. Fleming I, Schulz C, Fichtlscherer B, Kemp BE, Fisslthaler B, Busse R: AMP-activated protein kinase (AMPK) regulates the insulin-induced activation of the nitric oxide synthase in human platelets. Thromb Haemost 2003; 90: 863-871
220. Kagawa H, Komiyama Y, Nakamura S, Miyake T, Miyazaki Y, Hamamoto K, Masuda M, Takahashi H, Nomura S, Fukuhara S: Expression of functional tissue factor on small vesicles of lipopolysaccharide-stimulated human vascular endothelial cells. Thromb Res 1998; 91: 297-304
221. Chou J, Mackman N, Skoloff GM, Pedersen B, Furie BC, Furie B: Initiation and propagation of the arterial thrombus in vivo: contribution of vessel wall and blood-borne microparticle tissue factor. Blood 2003; 102(11): 6a #6
222. Bonderman D, Teml A, Jakowitsch J, Adlbrecht C, Gyongyosi M, Sperker W, Lass H, Mosgoeller W, Glogar DH, Probst P, Maurer G, Nemerson Y, Lang IM: Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99: 2794-2800
223. Shet AS, Aras O, Gupta K, Hass M, Solovey A, Key NS, Hebbel RP: Sickle blood contains tissue factor positive microparticles derived from endothelial cells and monocytes. Blood 2002; 100(11): 45a #157
224. Novotny WF, Girard TJ, Miletich JP, Broze GJ Jr: Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-2025
225. Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR: Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultra-structural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290-1299
226. Stringer HA, van Swieten P, Heijnen HF, Sixma JJ, Pannekoek H: Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop. Arterioscler Thromb 1994; 14: 1452-1458
227. Khetawat G, Faraday N, Nealen ML, Vijayan KV, Bolton E, Noga SJ, Bray PF: Human megakaryocytes and platelets contain the estrogen receptor beta and androgen receptor (AR): testosterone regulates AR expression. Blood 2000; 95: 2289-2296
228. Giandomenico G, Czekay RP, Koschnick S, Loskutoff DJ: Influence of leptin on platelet function. Blood 2003; 102(11): 69b #3981
229. Ghosh SA, Polanowska-Grabowska RK, Fujii J, Obrig T, Gear AR: Shiga toxin binds to activated platelets. J Thromb Haemost 2004; 2: 499-506
230. Hackeng CM, Relou IA, Pladet MW, Gorter G, van Rijn HJ, Akkerman JW: Early platelet activation by low density lipoprotein via p38MAP kinase. Thromb Haemost 1999; 82: 1749-1756
231. Akkerman JWN, Eybrechts KL, Kroner C, Ferreira IA: IRS-1 mediates platelet inhibition by insulin via the inhibitory G protein Gi. Blood 2003; 102(11): 775a #2861
232. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G: Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994; 203: 72-79
233. Philippeaux MM, Vesin C, Tacchini-Cottier F, Piguet PF: Activated human platelets express beta2 integrin. Eur J Haematol 1996; 56: 130-137
234. Nomura S, Komiyama Y, Miyake T, Miyazaki Y, Kido H, Suzuki M, Kagawa H, Yanabu M, Takahashi H, Fukuhara S: Amyloid beta-protein precursor-rich platelet microparticles in thrombotic disease. Thromb Haemost 1994; 72: 519-522
235. Cooling LL, Zhang DS, Walker KE, Koerner TA: Detection in human blood platelets of sialyl Lewis X gangliosides, potential ligands for CD62 and other selectins. Glycobiology 1995; 5: 571-581
236. Santoso S, Sachs UJH, Kroll H, Linder M, Ruf A, Preissner KT: JAM-3, a new platelet receptor for the Mac-1 integrin. Blood 2002; 100(11): 259a #988
237. Babinsky A, Kedees MH, Arthar H, Ahmed T, Batuman O, Erlich YH, Hussain MM, Kornecki E: F11 receptor (F11R/ JAM) mediates platelet adhesion to inflamed endothelial cells. Blood 2002; 100(11): 258a #984
238. Kornecki E, Babinska A, Kedees MH, Athar H, Sobocka MB, Sobacki T, Erlich YH, Hussain MM, Jiang XC: F11R, a platelet adhesion protein critical for the development of thrombosis and atherosclerosis. Blood 2002; 100(11): 75b #3772
239. Morgan BP: Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. Biochem J 1992; 282: 409-413
240. Horstman LL, Jy W, Morgan BP, Ahn YS: CD59 expression on platelets in ITP and PNH. La Revista de Investigacion Clinica (Suppl) 1994; 110: 212 #a109
241. Anker P, Stroun M: Progress in the knowledge of circulating nucleic acids: plasma RNA is particle-associated. Can it become a general detection marker for a cancer blood test? Clin Chem 2002; 48: 1210-1211
242. Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, Lo ES, Rainer TH, Johnson PJ, Lo YM: Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 2002; 48:1212-1217
243. Hasselmann DO, Rappl G, Tilgen W, Reinhold U: Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum. Clin Chem 2001; 47: 1488-1489
244. Favaloro EJ, Mohammed A, Coombs R, Mehrabani PA: Filtered plasma as a potential cause of clinical misdiagnosis: inappropriate testing in a haematology laboratory. Br J Biomed Sci 1995; 52: 243-248
245. Favaloro EJ, Nair SC, Forsyth CJ: Collection and transport of samples for laboratory testing in von Willebrand's disease (VWD): time for a reappraisal? Thromb Haemost 2001; 86: 1589-1590
246. Jiang N, Reich CF 3rd, Pisetsky DS: Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. Blood 2003; 102: 2243-2250
247. Savill J, Gregory C, Haslett C: Cell biology. Eat me or die. Science 2003; 302: 1516-1517
248. Park CT, Creasey AA, Wright SD: Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89: 4268-4274
249. Roberts JP: An immunological role in the CARDS. The Scientist 2003; 17: 29-30
250. Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton R, Cheng S, Shuldiner AR: Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290: 2030-2040
251. Lerch PG, Spycher MO, Doran JE: Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost 1998; 80: 316-320
252. Murai K, Kowata S, Sako M, Ito T, Inoue H, Kaneko Y, Nakai K, Ito E, Ishida Y: Thrombin-antithrombin III/HDL (high density lipoprotein) is one of the regulators of platelet production in chronic immune thrombocytopenia. Blood 2003; 102(11): 299a #1069
253. Dennis MW, Downey C, Brufatto N, Nesheim ME, Stevenson K, Hock Toh C: Prothrombinase enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein. Thromb Haemost 2004; 91: 522-530
254. Toh CH, Dennis MW, Colin D: Procoagulant enhancement through quantitative and qualitative changes affecting very low density lipoprotein in complex with C-reactive protein. Blood 2003; 102(11): 90b #4067
255. Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995; 15: 1764-1773
256. Hansen JB, Huseby NE, Sandset PM, Svensson B, Lyngmo V, Nordoy A: Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb 1994; 14: 223-229
257. Lesnik P, Vonica A, Guerin M, Moreau M, Chapman MJ: Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a). Arterioscler Thromb 1993; 13: 1066-1075
258. Polz E, Wurm H, Kostner GM: Investigations on beta 2-glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980; 11: 265-270
259. Jimenez JJ, Ferreira A, Peter A, Jy W, Mauro LM, Mendez AJ, deMarchena E, Soderland C, Horstman LL, Ahn YS: Elevated endothelial microparticles (EMP) and decreased endothelial progenitors are associated with increased serum cholesterol levels. Blood 2003; 102(11): 73b #3997
260. Sims PJ, Wiedmer T: The response of human platelets to activated components of the complement system. Immunol Today 1991; 12: 338-342
261. Wiedmer T, Sims PJ: Participation of protein kinases in complement C5b-9-induced shedding of platelet plasma membrane vesicles. Blood 1991; 78: 2880-2886
262. Haynes DH: Effects of cyclic nucleotides and protein kinases on platelet calcium homeostasis and mobilization. Platelets 1993; 4: 231-43
263. Zhou Q, Zhao J, Stout JG, Luhm RA, Wiedmer T, Sims PJ: Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem 1997; 272: 18240-18244
264. Zwaal RF, Comfurius P, Bevers EM: Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180: 1-8
265. Zwaal RF, Schroit AJ: Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132
266. Seymour CA, Muallem S, Lew VL: Preparation of inside-out vesicles from red blood cells in one step, In: Ellory JC, Young JD, eds, Red cell Membranes, a Methodological Approach, London/New York, Academic Press, 1982; 219-222
267. Racker E, Horstman LL: Partial resolution of the enzymes catalyzing oxidative phosphorylation. 13. Structure and function of submitochondrial particles completely resolved with respect to coupling factor. J Biol Chem 1967; 242: 2547-2551
268. Ahn YS, Jy W, Horstman LL, Jimenez JJ: Letter on review by JM Freyssinet. J Thromb Haemost 2004; (in press)
269. White JG: Functional significance of mobile receptors on human platelets. Arterioscler Thromb 1993; 13: 1236-1243
270. Nurden P: Bidirectional trafficking of membrane glycoproteins following platelet activation in suspension. Thromb Haemost 1997; 78: 1305-1315
271. Coller BS, Kutok JL, Scudder LE, Galanakis DK, West SM, Rudomen GS, Springer KT: Studies of activated GPIIb/IIIa receptors on the luminal surface of adherent platelets. Paradoxical loss of luminal receptors when platelets adhere to high density fibrinogen. J Clin Invest 1993; 92: 2796-2806
272. Simmons SR, Sims PA, Albrecht RM: alpha IIb beta 3 redistribution triggered by receptor cross-linking. Arterioscler Thromb Vasc Biol 1997; 17: 3311-3320
273. Bodin S, Viala C, Ragab A, Payrastre B: A critical role of lipid rafts in the organization of a key FcgammaRIIa-mediated signaling pathway in human platelets. Thromb Haemost 2003; 89: 318-330
274. Dietzen DJ, Jack GG, Page KL, Tetzloff TA, Hall CL, Mast AE: Localization of tissue factor pathway inhibitor to lipid rafts is not required for inhibition of factor VIIa/tissue factor activity. Thromb Haemost 2003; 89: 65-73
275. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39
276. Anderson RG, Jacobson K: A role for lipid shells in targeting proteins to caveolae, rafts, and other lipid domains. Science 2002; 296: 1821-1825
277. Czech MP: Lipid rafts and insulin action. Nature 2000; 407: 147-148
278. Simons K, Ikonen E: Functional rafts in cell membranes. Nature 1997; 387: 569-572
279. Freed EO: Virology. Rafting with Ebola. Science 2002; 296: 279
280. Frank PG, Woodman SE, Park DS, Lisanti MP: Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol 2003; 23: 1161-1618
281. Salzer U, Prohaska R: Stomatin, flotillin-1, and flotillin-2 are major integral proteins of erythrocyte lipid rafts. Blood 2001; 97: 1141-1143
282. Butikofer P, Kuypers FA, Xu CM, Chiu DT, Lubin B: Enrichment of two glycosyl-phosphatidylinositol-anchored proteins, acetylcholinesterase and decay accelerating factor, in vesicles released from human red blood cells. Blood 1989; 74: 1481-1485
283. Dietzen DJ, Page KL, Tetzloff TA: Lipid rafts are necessary for tonic inhibition of cellular tissue factor procoagulant activity. Blood 2003; 102(11): 791a #2926
284. Munday AD, Shrimpton CN, Lopez JA: Relationship of lipid rafts and the platelet cytoskeleton. Blood 2003; 102(11): 772a #2849
285. Sun J, Nanjundan M, Pike LJ, Wiedmer T, Sims PJ: Plasma membrane phospholipid scramblase 1 is enriched in lipid rafts and interacts with the epidermal growth factor receptor. Biochemistry 2002; 41: 6338-6345
286. Jy W, Jimenez JJ, Mauro LM, Ahn YS, Newton KR, Mendez AJ, Arnold PI, Schultz DR: Agonist-induced capping of adhesion proteins and microparticle shedding in cultures of human renal microvascular endothelial cells. Endothelium 2002; 9: 179-189
287. Millan J, Montoya MC, Sancho D, Sanchez-Madrid F, Alonso MA: Lipid rafts mediate biosynthetic transport to the T lymphocyte uropod subdomain and are necessary for uropod integrity and function. Blood 2002; 99: 978-984
288. Chonn A, Cullis PR, Devine DV: The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991; 146: 4234-4241
289. Morgan BP, Meri S: Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994; 15: 369-396
290. Horstman LL, Jy W, Schultz DR, Mao WW, Ahn YS: Complement-mediated fragmentation and lysis of opsonized platelets: ender differences in sensitivity. J Lab Clin Med 1994; 123: 515-525
291. Hamilton KK, Hattori R, Esmon CT, Sims PJ: Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem 1990; 265: 3809-3814
292. Taylor FB Jr, He SE, Chang AC, Box J, Ferrell G, Lee D, Lockhart M, Peer G, Esmon CT: Infusion of phospholipid vesicles amplifies the local thrombotic response to TNF and anti-protein C into a consumptive response. Thromb Haemost 1996; 75: 578-584
293. Jamil H, Sheikh S, Ahmad I: Liposomes: The next generation. Modern Drug Discovery 2004; Jan: 36-39
294. Sanchez-Mateos P, Campanero MR, del Pozo MA, Sanchez-Madrid F: Regulatory role of CD43 leukosialin on integrin-mediated T-cell adhesion to endothelial and extracellular matrix ligands and its polar redistribution to a cellular uropod. Blood 1995; 86: 2228-2239
295. Reed GL, Fitzgerald ML, Polgar J: Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. Blood 2000; 96: 3334-3342